MMAF intermediate 2

• CAT Number: I040440
• CAS Number: 864238-20-0
• Molecular Formula: C19H29ClN2O4
• Molecular Weight: 384.90
• Purity: ≥95%
• Synonyms: methyl (2S)-2-[[(2R,3R)-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanoyl]amino]-3-phenylpropanoate;hydrochloride
• InChI: InChI=1S/C19H28N2O4.ClH/c1-13(17(24-2)15-10-7-11-20-15)18(22)21-16(19(23)25-3)12-14-8-5-4-6-9-14;/h4-6,8-9,13,15-17,20H,7,10-12H2,1-3H3,(H,21,22);1H/t13-,15+,16+,17-;/m1./s1
• InChIKey: IKNWSNCMBMHJAU-WOLLCHHQSA-N
• SMILES: CC(C(C1CCCN1)OC)C(=O)NC(CC2=CC=CC=C2)C(=O)OC.Cl

MMAF Intermediate 2(CAT: I040440) is a key synthetic intermediate in the preparation of Monomethyl Auristatin F (MMAF, HY-15579), a potent antimitotic agent used as the cytotoxic payload in antibody-drug conjugates (ADCs). MMAF functions by inhibiting tubulin polymerization, leading to cell cycle arrest and apoptosis in proliferating cancer cells. As part of ADCs like Vorsetuzumab mafodotin and SGN-CD19A, MMAF provides targeted cytotoxicity with improved safety profiles. MMAF Intermediate 2 plays a crucial role in the stepwise construction of this highly active compound, supporting efficient synthesis workflows in the development of next-generation targeted cancer therapies. Ideal for ADC payload research and manufacturing.

Reference

\MMAF Intermediate 2 is a key synthetic intermediate in the preparation of Monomethyl Auristatin F (MMAF, HY-15579), a potent antimitotic agent used as the cytotoxic payload in antibody-drug conjugates (ADCs). MMAF functions by inhibiting tubulin polymerization, leading to cell cycle arrest and apoptosis in proliferating cancer cells. As part of ADCs like Vorsetuzumab mafodotin and SGN-CD19A, MMAF provides targeted cytotoxicity with improved safety profiles. MMAF Intermediate 2 plays a crucial role in the stepwise construction of this highly active compound, supporting efficient synthesis workflows in the development of next-generation targeted cancer therapies. Ideal for ADC payload research and manufacturing.